Drug Profile
Research programme: theranostics - NuvOx Pharma
Alternative Names: Thy-1 targeted microbubblesLatest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Developer NuvOx Pharma; Stanford University
- Class Anti-infectives; Anti-ischaemics; Antineoplastics; Eye disorder therapies; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers; Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atherosclerosis; Bacterial endocarditis; Breast cancer; Pancreatic cancer; Uveitis
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Atherosclerosis (Diagnosis) in USA (unspecified route) (NuvOx Pharma website, September 2023)
- 03 Oct 2023 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route) (NuvOx Pharma website, September 2023)
- 03 Oct 2023 Discontinued - Preclinical for Bacterial endocarditis (Diagnosis) in USA (unspecified route) (NuvOx Pharma website, September 2023)